Test)

relimg2

April – the Month of Parkinson’s Disease Awareness


April 11 is the World Parkinson’s Disease Day and marks the birthday of Dr. J Parkinson who first described the disease in “An Essay on the Shaking Palsy” in 1817. He described a pattern of lessened muscular power and involuntary tremulous motion. There is at tendency to bend the body forwards, and to involuntarily switch from a walking to a running pace, while the sense and intellect deteriorate. This year the day marks 200 years since Parkinson’s disease was discovered.

The month of April is dedicated to raise awareness of the Parkinson’s disease and promoting a greater understanding of the condition and how it can affect a person. Parkinson’s disease is the second most-common neurological disease, affecting more than 10 million people worldwide. The disease is expected to lead to an increasing social and economic burden on societies as populations age.

The unmet medical need of Parkinson’s disease is high due to the lack of pharmaceutical agents affecting the underlying pathology in this disorder. Current treatments are symptomatic and do not halt or modify the disease progression.

Mutations in alpha-synuclein are strongly linked to development of Parkinson’s disease. Soluble aggregates of the alpha-synuclein protein are toxic to neurons and lead to the deposits that are a hallmark of the disease.

In September 2016, BioArctic entered into a strategically important collaboration with AbbVie to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications. The company’s antibody (BAN0805) is in preclinical development.

Gunilla Osswald, CEO: “With patients in mind, we strive to transform the treatment regimen of a neurodegenerative disease like Parkinson’s disease. Together with our partner AbbVie we are truly committed to do our outmost to bring an innovative disease modifying treatment to the large number of patients suffering from Parkinson’s disease.”

At the recent International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria, BioArctic presented the poster entitled: Intramuscular injection of sonicated α-synuclein fibrils induces α-synuclein pathology and motor deficits in h[A30P]αSYN transgenic mice. To access the poster.


For more information, please contact:
Gunilla Osswald, CEO, BioArctic AB
Christer Möller, CSO, BioArctic AB
Telephone +46 (0)8 695 6930